Yi Zhao1, Xin Wang2,3,4,5. 1. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No. 324, Jingwu Road, Jinan, 250021, Shandong, People's Republic of China. 2. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No. 324, Jingwu Road, Jinan, 250021, Shandong, People's Republic of China. xinw@sdu.edu.cn. 3. School of Medicine, Shandong University, Jinan, 250012, Shandong, China. xinw@sdu.edu.cn. 4. Shandong Provincial Engineering Research Center of Lymphoma, Jinan, 250021, Shandong, China. xinw@sdu.edu.cn. 5. Key Laboratory for Kidney Regeneration of Shandong Province, Jinan, 250021, Shandong, China. xinw@sdu.edu.cn.
Abstract
PURPOSE: Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates centriole duplication. PLK4 deregulation causes centrosome number abnormalities, mitotic defects, chromosomal instability and, consequently, tumorigenesis. Therefore, PLK4 has emerged as a therapeutic target for the treatment of multiple cancers. In this review, we summarize the critical role of centrosome amplification and PLK4 in cancer. We also highlight recent advances in the development of PLK4 inhibitors and discuss potential combination therapies for cancer. METHODS: The relevant literature from PubMed is reviewed in this article. The ClinicalTrials.gov database was searched for clinical trials related to the specific topic. RESULTS: PLK4 is aberrantly expressed in multiple cancers and has prognostic value. Targeting PLK4 with inhibitors suppresses tumor growth in vitro and in vivo. CONCLUSIONS: PLK4 plays an important role in centrosome amplification and tumor progression. PLK4 inhibitors used alone or in combination with other drugs have shown significant anticancer efficacy, suggesting a potential therapeutic strategy for cancer. The results of relevant clinical trials await evaluation.
PURPOSE:Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates centriole duplication. PLK4 deregulation causes centrosome number abnormalities, mitotic defects, chromosomal instability and, consequently, tumorigenesis. Therefore, PLK4 has emerged as a therapeutic target for the treatment of multiple cancers. In this review, we summarize the critical role of centrosome amplification and PLK4 in cancer. We also highlight recent advances in the development of PLK4 inhibitors and discuss potential combination therapies for cancer. METHODS: The relevant literature from PubMed is reviewed in this article. The ClinicalTrials.gov database was searched for clinical trials related to the specific topic. RESULTS:PLK4 is aberrantly expressed in multiple cancers and has prognostic value. Targeting PLK4 with inhibitors suppresses tumor growth in vitro and in vivo. CONCLUSIONS:PLK4 plays an important role in centrosome amplification and tumor progression. PLK4 inhibitors used alone or in combination with other drugs have shown significant anticancer efficacy, suggesting a potential therapeutic strategy for cancer. The results of relevant clinical trials await evaluation.
Authors: Ryan A Denu; Maria Shabbir; Minakshi Nihal; Chandra K Singh; B Jack Longley; Mark E Burkard; Nihal Ahmad Journal: Mol Cancer Res Date: 2018-01-12 Impact factor: 5.852
Authors: Ryan A Denu; Lauren M Zasadil; Craig Kanugh; Jennifer Laffin; Beth A Weaver; Mark E Burkard Journal: BMC Cancer Date: 2016-01-29 Impact factor: 4.430
Authors: Paula A Coelho; Leah Bury; Marta N Shahbazi; Kifayathullah Liakath-Ali; Peri H Tate; Sam Wormald; Christopher J Hindley; Meritxell Huch; Joy Archer; William C Skarnes; Magdalena Zernicka-Goetz; David M Glover Journal: Open Biol Date: 2015-12 Impact factor: 6.411
Authors: Danielle B Buglak; Erich J Kushner; Allison P Marvin; Katy L Davis; Victoria L Bautch Journal: Angiogenesis Date: 2020-07-22 Impact factor: 9.596